TABLE 3.
Baseline and demographic characteristics of different comparison patterns after PSM
| Comparison pattern 1 | Comparison pattern 2 | Comparison pattern 3 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Chemotherapy (N = 139) | Chemotherapy plus PTR (N = 139) | p | Chemoradiotherapy (N = 22) | Chemoradiotherapy plus PTR (N = 22) | p | No treatment (N = 73) | PTR only (N = 73) | p | |
| Age | 64 (57–71) | 65 (58–71) | 0.6 | 63 (54–72) | 61 (56–67) | 0.481 | |||
| Female | 72 (51.8) | 59 (42.4) | 0.149 | 13 (59.1) | 10 (45.5) | 0.546 | 41 (56.2) | 42 (57.5) | 0.867 |
| Race | |||||||||
| White | 107 (77.0) | 108 (77.7) | 0.805 | 20 (90.9) | 20 (90.9) | 1 | 56 (76.7) | 56 (76.7) | 0.585 |
| Black | 16 (11.5) | 18 (12.9) | 1 (4.5) | 1 (4.5) | 8 (11) | 11 (15.1) | |||
| Other | 16 (11.5) | 13 (9.4) | 1 (4.5) | 1 (4.5) | 9 (12.3) | 9 (12.3) | |||
| Grade | |||||||||
| I | 7 (5.0) | 8 (5.8) | 0.656 | 2 (9.1) | 1 (4.5) | 0.727 | 6 (8.2) | 7 (9.6) | 0.222 |
| II | 40 (28.8) | 43 (30.9) | 4 (18.2) | 7 (31.8) | 22 (30.1) | 27 (37) | |||
| III | 35 (25.2) | 41 (29.5) | 5 (22.7) | 4 (18.2) | 12 (16.4) | 18 (24.7) | |||
| IV | 1 (0.7) | 0 (0.0) | 0 (0) | 0 (0) | 2 (2.7) | 0 (0) | |||
| Unknown | 56 (40.3) | 47 (33.8) | 11 (50.0) | 10 (45.5) | 31 (42.5) | 21 (28.8) | |||
| T stage | |||||||||
| 1 | 7 (5.0) | 10 (7.2) | 0.608 | 2 (9.1) | 1 (4.5) | 0.962 | 7 (9.6) | 4 (5.5) | 0.825 |
| 2 | 53 (38.1) | 61 (43.9) | 10 (45.5) | 9 (40.9) | 27 (37) | 24 (32.9) | |||
| 3 | 42 (30.2) | 40 (28.8) | 4 (18.2) | 5 (22.7) | 17 (23.3) | 19 (26) | |||
| 4 | 25 (18.0) | 17 (12.2) | 4 (18.2) | 5 (22.7) | 11 (15.1) | 12 (16.4) | |||
| Unknown | 12 (8.6) | 11 (7.9) | 2 (9.1) | 2 (9.1) | 11 (15.1) | 14 (19.2) | |||
| N stage | |||||||||
| 0 | 40 (28.8) | 42 (30.2) | 0.58 | 8 (36.4) | 10 (45.5) | 0.812 | 17 (23.3) | 15 (20.5) | 0.926 |
| 1 | 38 (27.3) | 29 (20.9) | 4 (18.2) | 3 (13.6) | 20 (27.4) | 18 (24.7) | |||
| 2 | 3 (2.2) | 5 (3.6) | 0 (0.0) | 0 (0.0) | 4 (5.5) | 4 (5.5) | |||
| Unknown | 58 (41.7) | 63 (45.3) | 10 (45.5) | 9 (40.9) | 32 (43.8) | 36 (49.3) | |||
| Tumor location | |||||||||
| Head | 78 (56.1) | 73 (52.5) | 0.834 | 16 (72.7) | 13 (59.1) | 0.65 | 36 (49.3) | 35 (47.9) | 0.974 |
| Bodytail | 42 (30.2) | 48 (34.5) | 5 (22.7) | 7 (31.8) | 23 (31.5) | 22 (30.1) | |||
| Overlapping | 9 (6.5) | 7 (5.0) | 1 (4.5) | 1 (4.5) | 3 (4.1) | 4 (5.5) | |||
| Other | 10 (7.2) | 11 (7.9) | 0 (0.0) | 1 (4.5) | 11 (15.1) | 12 (16.4) | |||
| Msite bone | 1 (0.7) | 3 (2.2) | 0.615 | 1 (4.5) | 0 (0.0) | 1 | 2 (2.7) | 3 (4.1) | 0.649 |
| Msite brain | 0 (0.0) | 0 (0.0) | \ | 0 (0.0) | 0 (0.0) | \ | 0 (0) | 0 (0) | \ |
| Msite liver | 76 (54.7) | 90 (64.7) | 0.112 | 12 (54.5) | 11 (50.0) | 1 | 34 (46.6) | 40 (54.8) | 0.321 |
| Msite lung | 15 (10.8) | 13 (9.4) | 0.842 | 2 (9.1) | 1 (4.5) | 1 | 10 (13.7) | 9 (12.3) | 0.806 |
| Msite number | |||||||||
| 0 | 52 (37.4) | 41 (29.5) | 0.306 | 7 (31.8) | 10 (45.5) | 0.353 | 32 (43.8) | 25 (34.2) | 0.413 |
| 1 | 82 (59.0) | 90 (64.7) | 15 (68.2) | 12 (54.5) | 36 (49.3) | 44 (60.3) | |||
| 2 | 5 (3.6) | 8 (5.8) | 0 (0.0) | 0 (0.0) | 5 (6.8) | 4 (5.5) | |||
| 3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||
| 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||
| Insurance status | |||||||||
| Insured | 135 (97.1) | 135 (97.1) | 0.766 | 20 (90.9) | 21 (95.5) | 1 | 70 (95.9) | 69 (94.5) | 0.843 |
| Uninsured | 2 (1.4) | 3 (2.2) | 0 (0) | 0 (0) | 1 (1.4) | 2 (2.7) | |||
| Unknown | 2 (1.4) | 1 (0.7) | 2 (9.1) | 1 (4.5) | 2 (2.7) | 2 (2.7) | |||
| Married | 87 (62.6) | 92 (66.2) | 0.616 | 15 (68.2) | 13 (59.1) | 0.754 | 43 (58.9) | 40 (54.8) | 0.616 |
| Distant/reginal site resection | 47 (33.8) | 37 (26.6) | 0.24 | 7 (31.8) | 7 (31.8) | 1 | 21 (28.8) | 19 (26) | 0.711 |
PTR,.primary tumor resection. Msite, metastatic site.